Ignite Creation Date:
2024-05-06 @ 1:23 PM
Last Modification Date:
2024-10-26 @ 1:13 PM
Study NCT ID:
NCT04001569
Status:
UNKNOWN
Last Update Posted:
2019-06-28
First Post:
2019-06-23
Brief Title:
AZD8186 and Paclitaxel in Advanced Gastric Cancer
Sponsor:
Seoul National University Bundang Hospital
Organization:
Seoul National University Bundang Hospital
Study Overview
Official Title:
Phase1b2 Study of AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer
Status:
UNKNOWN
Status Verified Date:
2019-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
AZD8186 is an orally-dosed selective Phosphatidylinositol 3-kinase PI3K βδ inhibitor that binds to PI3Kβ and PI3Kδ and inhibits kinase activity and downstream pathways in vitro and in vivo AZD8186 has shown significant anti-tumor activity in PTEN-deficient preclinical models including prostate triple negative breast cancer squamous lung and germinal center diffuse large B-cell lymphoma models PTEN deficiency is reported in approximately 20 of patients with gastric cancer and in 35-48 of those with human epidermal growth factor receptor 2HER2-positive gastric cancer To date there have been no clinical trials with AZD8186 alone or in combination with paclitaxel in advanced gastric cancer Therefore it is very important to conduct clinical trials of combination therapy of AZD8186 and paclitaxel in patients with metastaticrecurrent gastric cancer who have failed previous therapy and to identify the clinical factors and biomarkers that predict effects of the combination therapy
The purpose of the study is to define the maximal tolerated dose MTD and recommended phase 2 dose RP2D of paclitaxel and AZD8186 combination therapy in patients with advanced tumors and to evaluate the efficacy of paclitaxel and AZD8186 combination therapy as a second-line therapy in patients with advanced gastric cancer with PTEN aberrations This study is divided into Phase 1b and Phase 2
The purpose of the study is to define the maximal tolerated dose MTD and recommended phase 2 dose RP2D of paclitaxel and AZD8186 combination therapy in patients with advanced tumors and to evaluate the efficacy of paclitaxel and AZD8186 combination therapy as a second-line therapy in patients with advanced gastric cancer with PTEN aberrations This study is divided into Phase 1b and Phase 2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None